The results from this 5-year, open-label extension trial affirm the safety of dupilumab in adults with moderate to severe AD.
This article was originally published by Dermatology Times.
An open-label extension study (NCT01949311) has demonstrated acceptable safety of dupilumab (Dupixent) in treating adult patients with moderate to severe atopic dermatitis (AD) for up to 5 years, according to results presented in a poster session at the 2023 Fall Clinical Dermatology Conference in Las Vegas, Nevada.
The LIBERTY AD OLE trial involved a multicenter, phase 3 study that extended for up to 5 years. Adult patients with moderate to severe AD, who had previously participated in dupilumab clinical trials, received a weekly dose of 300 mg. Some patients transitioned to 300 mg every 2 weeks (q2w) to align with approved dosage.
Concomitant treatments, including topical corticosteroids (TCS) and topical calcineurin inhibitors, were allowed. The study lacked a control arm, so data from the LIBERTY AD CHRONOS trial provided comparative 52-week safety results for patients receiving dupilumab 300 mg qw plus TCS.
Adult patient with atopic dermatitis (AD)
Image credit: Monstar Studios - stock.adobe.com
The OLE trial included 2677 patients, with 60.2% being male and 72.3% identifying as White. The mean age of patients was 39.2 years, and the average duration of AD was 29.9 years. Baseline scores for Eczema Area and Severity Index, Investigator’s Global Assessment, and Peak Pruritus Numerical Rating Scale were 16.4, 2.7, and 5.0, respectively.
The safety profile of long-term dupilumab treatment for up to 5 years was found to be acceptable and consistent with previous findings from placebo-controlled studies. Exposure-adjusted incidence rates of treatment-emergent adverse events (TEAEs) did not increase over time and were lower than those reported in the 3- and 4-year analyses of the OLE trial and a previous 52-week placebo-controlled trial.
The results from this 5-year open-label extension trial affirm the safety of dupilumab in adults with moderate to severe AD and provide valuable insights for clinicians considering long-term treatment options for their patients. Continued monitoring and research in this area will further enhance understanding of dupilumab's safety profile.
Reference
Beck L, Bissonnette R, Deleuran M, et al. Safety of long-term dupilumab treatment in adults with moderate-to-severe results from a 5-year open-label extension trial. Poster presented at: 2023 Fall Clinical Dermatology Conference; October 19-22, 2023; Las Vegas, Nevada.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Bimekizumab-bkzx, the Newest Psoriasis Treatment, Is Now Available
November 30th 2023Bimekizumab-bkzx (Bimzelx) is the first dual interleukin 17A (IL-17A) and interleukin 17F (IL-17F) inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7200 per syringe.
Read More
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More